| Parameter (normal range) | Day 1 | Day 8 | Day 15 | Day 22 | Day 29 | Day 44 | Day 54 | Day 114 | Day 165 |
| C-reactive protein (<10 mg/l) | 7 | 8 | 5 | 9 | 9 | – | 24 | <5 | 5 |
| Sedimentation rate (2–20 mm/h) | – | – | 24 | 24 | 34 | – | – | 25 | 12 |
| Serum orosomucoid† (0.83–1.08 g/l) | 1.11 | 1.04 | – | 1.02 | – | 1.41 | – | 0.93 | 0.80 |
| Haemoglobin‡ (7.0–10.0 mmol/l) | 7.7 | 7.1 | 7.0 | 7.2 | 7.3 | 7.4 | 7.1 | 7.1 | 7.5 |
| Leukocytes (3.0–10.0×109/l) | 6.7 | 5.3 | 6.4 | 5.3 | 9.0 | 10.1 | 8.1 | 5.5 | 6.0 |
| Thrombocytes (120–400×109/l) | 330 | 321 | 341 | 367 | 343 | 374 | 399 | 363 | 289 |
| Immunoglobulin A (0.70–3.65 g/l) | 1.75 | – | – | – | – | – | 1.79 | 1.75 | – |
| Immunoglobulin G (6.9–15.7 g/l) | 12.8 | – | – | – | – | – | 11.4 | 11.9 | – |
| Immunoglobulin M (0.55–2.30 g/l) | 1.27 | – | – | – | – | – | 1.08 | 1.12 | – |
*Rituximab was given at days 1, 8, 15 and 22. Normal ranges are given in the parentheses.
†The given orosomucoid levels were measured on stored samples. The patient’s primary disease (Graves’ disease) and her anti-thyroid drug therapy may have affected the orosomucoid levels.
‡Iron supplementation therapy was initiated at day 113.